Dianthus Therapeutics, Inc. DNTH

DNTH Company Overview

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of targeted therapies for severe autoimmune and inflammatory diseases. The company operates within the biopharmaceutical and immunology sectors, with a strategic emphasis on conditions driven by the classical complement pathway of the immune system. Dianthus does not currently generate commercial product revenue and is primarily funded through equity financing to support research and clinical development activities.

The company’s primary asset is DNTH103, a monoclonal antibody designed to selectively inhibit C1s, a key component of the classical complement pathway. This targeted approach is intended to suppress pathogenic inflammation while preserving broader immune function. Dianthus aims to serve patients with rare and serious autoimmune diseases, initially focusing on generalized myasthenia gravis and other complement-mediated disorders. The company positions itself as a precision-immunology developer with potential differentiation based on pathway selectivity and safety profile.

Dianthus Therapeutics was founded in 2019 and became a publicly traded company in 2023 following a reverse merger with Magenta Therapeutics, Inc., after which it began trading on Nasdaq under the ticker DNTH. The merger provided Dianthus with public market access and capital resources while discontinuing Magenta’s prior transplant-focused programs.